Clinical Trial Update: DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 study evaluating the tolerability of BI 764532 in combination with chemotherapy in patients with advanced neuroen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• BI 764532 (BI 764532)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Neuroendocrine Neoplasms | Phase 1 | Status: RECRUITING